Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

BMC Psychiatry, Journal Year: 2020, Volume and Issue: 20(1)

Published: Jan. 16, 2020

Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. been reported have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, intractable childhood epilepsy. Yet its application the field of psychiatry is lesser known.The first clinically-focused systematic review on emerging medical across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations plant-derived cannabinoid isolates mood, anxiety, sleep, psychotic deficit/hyperactivity disorder (ADHD) discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational public health elements, future recommendations. The literature conducted during 2019, assessing data from case studies trials involving medicinal or for (neurological conditions pain were omitted).The present therapeutics nascent, thereby it currently premature recommend cannabinoid-based interventions. Isolated positive have, however, revealed tentative support cannabinoids (namely cannabidiol; CBD) social anxiety; with mixed (mainly positive) adjunctive use schizophrenia. Case suggest that may be beneficial improving sleep post-traumatic stress disorder, however weak. Preliminary findings indicate no benefit depression high delta-9 tetrahydrocannabinol (THC) therapeutics, CBD mania. One isolated study indicates some an oral cannabinoid/terpene combination ADHD. Clinical prescriptive consideration involves caution high-THC (avoidance youth, people anxiety disorders), gradual titration, regular assessment, cardiovascular respiratory disorders, pregnancy breast-feeding.There encouraging, albeit embryonic, treatment a range disorders. Supportive are key isolates, clinicians need mindful safety considerations, especially if initiating higher dose THC formulas.

Language: Английский

---

A systematic review of cannabidiol dosing in clinical populations

British Journal of Clinical Pharmacology, Journal Year: 2019, Volume and Issue: 85(9), P. 1888 - 1900

Published: June 21, 2019

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in wide‐variety of contexts; however, its effective dose different disease states remains unclear. This review aimed to investigate what doses have been applied clinical populations, order understand the active range CBD variety medical contexts. Methods Publications involving administration alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total 1038 articles retrieved, which 35 studies met inclusion criteria covering 13 Twenty‐three reported significant improvement primary outcomes (e.g. psychotic symptoms, anxiety, seizures), ranging between <1 50 mg/kg/d. Plasma concentrations not provided any publication. was as well tolerated epilepsy most frequently studied condition, all 11 demonstrating positive effects on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There no signal activity small trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver chronic pain. However, low 2.4 mg/kg/d) used these studies. Conclusion highlights that has wide several pathologies. Pharmacokinetic conclusive phase III elucidate plasma contexts are severely lacking highly encouraged.

Language: Английский

---

Towards Better Delivery of Cannabidiol (CBD)

Pharmaceuticals, Journal Year: 2020, Volume and Issue: 13(9), P. 219 - 219

Published: Aug. 28, 2020

Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered intrinsic characteristics such low bioavailability, water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability substance also limits likelihood expensive, full programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying delivery systems, improved crystal formulations solid-state formulations, which are mostly pre-clinical or early clinical stages development. This review identifies compromising current CBD, how advanced strategies can enable realise potential a successful agent.

Language: Английский

---

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Journal of Clinical Medicine Research, Journal Year: 2020, Volume and Issue: 12(3), P. 129 - 141

Published: Jan. 1, 2020

Considering data from in vitro and vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic psychiatric disorders. The aim this review was collect dose(s), dosage schemes, efficacy safety reports CBD use adults clinical studies. A systematic search performed PubMed, Embase Cochrane library articles published English between January 1, 2000 October 25, 2019. terms used were related cannabis adults. We identified 25 studies (927 patients; 538 men 389 women), which 22 controlled trials (833 patients) three observational designs (94 five countries. Formulations, dose schemes varied significantly Varying effects randomized (RCTs), more apparent non-RCTs minor issues general. From trials, we anxiolytic with acute administration, therapeutic social anxiety disorder, psychotic disorder substance In general, heterogeneous showed substantial risks bias. Although results have been identified, considerable variation route administration employed across There evidence support single positive effect on short medium-term symptomatic improvement schizophrenia lack cognitive functioning Overall, well tolerated mild side effects. J Clin Med Res. 2020;12(3):129-141 doi: https://doi.org/10.14740/jocmr4090

Language: Английский

---

Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems

Journal of Cannabis Research, Journal Year: 2021, Volume and Issue: 3(1)

Published: Feb. 18, 2021

Abstract Background Public and medical interest in cannabidiol (CBD) has been rising, CBD is now available from various sources. Research into the effects of low-dose on outcomes like stress, anxiety, sleep problems have scarce, so we conducted an online survey users to better understand patterns use, dose, self-perceived CBD. Methods The sample consisted 387 current or past-CBD who answered a 20-question survey. was sent out through email databases social media. Participants reported basic demographics, use patterns, reasons for sleep, stress. Results ( N = 387) 61.2% females, mostly between 25 54 years old (72.2%) primarily based UK (77.4%). top 4 using were anxiety (42.6%), (42.5%), stress (37%), general health wellbeing (37%). Fifty-four per cent less than 50 mg daily, 72.6% used sublingually. Adjusted logistic models show females had lower odds males [OR 0.45, 95% CI 0.30–0.72] post-workout muscle-soreness 0.46, 95%CI 0.24–0.91] but higher 1.60, 0.02–2.49] insomnia 1.87, 1.13–3.11]. Older individuals wellbeing, sore muscles, skin conditions, focusing, pain. Respondents that effective problems, those drug conditions. Conclusion This indicated take manage other symptoms, often low doses, these vary by demographic characteristics. Further research required how representative user, might impact mental symptoms problems.

Language: Английский

---

Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial

Annals of Oncology, Journal Year: 2020, Volume and Issue: 31(11), P. 1553 - 1560

Published: Aug. 13, 2020

Language: Английский

---

The potential of cannabidiol in the COVID‐19 pandemic

British Journal of Pharmacology, Journal Year: 2020, Volume and Issue: 177(21), P. 4967 - 4970

Published: June 10, 2020

Identifying drugs effective in the new coronavirus disease 2019 (COVID‐19) is crucial, pending a vaccine against SARS‐CoV2. We suggest hypothesis that cannabidiol (CBD), non‐psychotropic phytocannabinoid, has potential to limit severity and progression of for several reasons:‐ (a) High‐cannabidiol Cannabis sativa extracts are able down‐regulate expression two key receptors SARS‐CoV2 models human epithelia, (b) exerts wide range immunomodulatory anti‐inflammatory effects it can mitigate uncontrolled cytokine production responsible acute lung injury, (c) being PPARγ agonist, display direct antiviral activity (d) agonists regulators fibroblast/myofibroblast activation inhibit development pulmonary fibrosis, thus ameliorating function recovered patients. hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies test as support drug COVID‐19 pandemic. Linked Articles This article part themed issue on The Pharmacology COVID‐19. To view other articles this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc

Language: Английский

---

Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol

Pharmacological Research, Journal Year: 2020, Volume and Issue: 157, P. 104822 - 104822

Published: April 23, 2020

Language: Английский

---

Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis

Neuroscience & Biobehavioral Reviews, Journal Year: 2019, Volume and Issue: 108, P. 358 - 369

Published: Nov. 9, 2019

Language: Английский

---

Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts

Cell Death and Disease, Journal Year: 2020, Volume and Issue: 11(8)

Published: Sept. 1, 2020

Abstract Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from cannabis sativa that has demonstrated anti-inflammatory effects in several inflammatory conditions including arthritis. However, CBD binds to receptors and enzymes and, therefore, its mode of action remains elusive. In this study, we show increases intracellular calcium levels, reduces cell viability IL-6/IL-8/MMP-3 production rheumatoid arthritis synovial fibroblasts (RASF). These were pronounced under by activating transient receptor potential ankyrin (TRPA1), opening the mitochondrial permeability transition pore. Changes determined using fluorescent dyes Cal-520/PoPo3 together with titer blue luminescent dye RealTime-glo. Cell-based impedance measurements conducted XCELLigence system TRPA1 protein was detected flow cytometry. Cytokine evaluated ELISA. reduced viability, proliferation, IL-6/IL-8 RASF. Moreover, increased uptake cationic PoPo3 RASF, which enhanced pre-treatment TNF. Concomitant incubation antagonist A967079 but not TRPV1 capsazepine on uptake. addition, an inhibitor pore, cyclosporin A, also blocked IL-8 production. inhibited voltage-dependent anion-selective channel DIDS Decynium-22, for all organic cation transporter isoforms. RASF targets. This effect TNF suggesting preferentially targets activated, pro-inflammatory Thus, possesses anti-arthritic activity might ameliorate via targeting conditions.

Language: Английский

---